AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26390920 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose PDT
Number of subjects: 156
Study 26390920 — intervention group
Group type: COMPARATOR
Intervention: HSML
Number of subjects: 156
Study 24041010 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-Pan (0.9 μg HA)
Number of subjects: 543
Study 24041010 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Pan (0.9 μg HA)
Number of subjects: 543
Study 24041010 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-Pan (1.9 μg HA)
Number of subjects: 543
Study 24041010 — intervention group
Group type: COMPARATOR
Intervention: Q-Pan
Number of subjects: 543
Study 24041010 — intervention group
Group type: COMPARATOR
Intervention: D-Pan
Number of subjects: 543
Study 21837752 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily)
Number of subjects: 30
Study 21837752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21837752 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐790052
Number of subjects: 30
Study 19293342 — intervention group
Group type: EXPERIMENTAL
Intervention: ARD-07 with food (0.5 mg/kg)
Number of subjects: 16
Study 19293342 — intervention group
Group type: COMPARATOR
Intervention: ARD-07 without food (0.5 mg/kg)
Number of subjects: 16
Study 17227321 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 347
Study 17227321 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 347
Study 15693705 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract A: caffeoylquinic acids equivalent to 107.0 mg caffeic acid and luteolin glycosides equivalent to 14.4 mg luteolin
Number of subjects: 14
Study 15693705 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract B: caffeoylquinic acids equivalent to 153.8 mg caffeic acid and luteolin glycosides equivalent to 35.2 mg luteolin
Number of subjects: 14
Study 15693705 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteolin administered as glucoside
Number of subjects: 14
Study 11789734 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for prothrombin time (PT)
Number of subjects: 42
Study 11789734 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for activated partial thromboplastin time (aPTT)
Number of subjects: 42
Study 11789734 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic agents (aprotinin, epsilon-aminocaproic acid)
Number of subjects: 42
Study 11789734 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study 9814109 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures for varicocele correction
Number of subjects: 66
Study 8073778 — intervention group
Group type: EXPERIMENTAL
Intervention: Melbrosia
Number of subjects: 0
Study 8073778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2913775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 15
Study 2913775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 2913775 — intervention group
Group type: COMPARATOR
Intervention: Prazosin and Propranolol
Number of subjects: 15
Study 30452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 1996
Study 30452928 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1996
Study 30452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ln-transformed FGF21 levels at randomization
Number of subjects: 1996
Study 30452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ln-transformed FGF21 levels at 1-year post-randomization
Number of subjects: 1996
Study 30452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in FGF21 levels over 1-year
Number of subjects: 1996
Study 30452928 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF21 levels
Number of subjects: 1996
Study 29212477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led health and lifestyle modification program
Number of subjects: 0
Study 29212477 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 25455795 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (HI) with six booster sessions over 3 months
Number of subjects: 34
Study 25455795 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (HI)
Number of subjects: 34
Study 25455795 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity training
Number of subjects: 34
Study 23670995 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 201
Study 23670995 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 201
Study 23670995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 201
Study 23670995 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased estimated METs
Number of subjects: 201
Study 23670995 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased estimated METs and reduced waist circumference
Number of subjects: 201
Study 21272196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0
Study 21272196 — intervention group
Group type: COMPARATOR
Intervention: Callisthenic exercise
Number of subjects: 0
Study 19485587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127
Study 15505645 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural honey
Number of subjects: 20
Study 15505645 — intervention group
Group type: COMPARATOR
Intervention: Eusol solution
Number of subjects: 20
Study 10228190 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of infliximab per kilogram
Number of subjects: 94
Study 10228190 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of infliximab per kilogram
Number of subjects: 94
Study 10228190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Number of subjects: 200
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone
Number of subjects: 200
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate
Number of subjects: 200
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 200
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate (after nonamphetamine therapies)
Number of subjects: 200
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate (urinary excretion <75%)
Number of subjects: 200
Study 15251577 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate (urinary excretion <55%)
Number of subjects: 200
Study 2101059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (6.25, 8.75 and 11.25 mg)
Number of subjects: 14
Study 2101059 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.1875, 0.375 and 0.5 mg)
Number of subjects: 14
Study 2101059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2101059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 14
Study 2101059 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 14
Study 6969081 — intervention group
Group type: EXPERIMENTAL
Intervention: Metocurine 0.45 mg kg‐1
Number of subjects: 20
Study 6969081 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 20
Study 30472236 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrilumab 70 mg
Number of subjects: 354
Study 30472236 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrilumab 210 mg
Number of subjects: 354
Study 30472236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 28702870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (n = 86)
Number of subjects: 244
Study 28702870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Suggestion (n = 73)
Number of subjects: 244
Study 28702870 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (n = 85)
Number of subjects: 244
Study 26433959 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m(2), Cisplatin 40 mg/m(2)
Number of subjects: 18
Study 26433959 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m(2), Cisplatin 50 mg/m(2)
Number of subjects: 18
Study 26433959 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 105 mg/m(2), Cisplatin 50 mg/m(2)
Number of subjects: 18
Study 26433959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic IMRT with concurrent TP
Number of subjects: 18
Study 24268211 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1100
Study 24268211 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (600 mg/d for 10 days, then 200-400 mg/d until the end of the study)
Number of subjects: 1100
Study 24268211 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 1100
Study 24268211 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 1100
Study 21332299 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20
Study 21332299 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental Treatment (NDT)
Number of subjects: 20
Study 19203392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of metformin daily
Number of subjects: 58
Study 19203392 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 58
Study 17338714 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient overdrive pacing (at 35 bpm above baseline) for 2 minutes upon standing
Number of subjects: 62
Study 17338714 — intervention group
Group type: COMPARATOR
Intervention: Control with backup pacing (60 bpm)
Number of subjects: 62
Study 17338714 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient overdrive pacing in OH patients with CI
Number of subjects: 62
Study 17338714 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient overdrive pacing in OH patients without CI
Number of subjects: 62
Study 15569164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held computers
Number of subjects: 41
Study 15569164 — intervention group
Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 41
Study 11180995 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 47
Study 11180995 — intervention group
Group type: COMPARATOR
Intervention: Nonseptic control patients
Number of subjects: 47
Study 9510365 — intervention group
Group type: COMPARATOR
Intervention: MMC 40 mg (retained in the bladder for 2 hours) once a week for 8 weeks (group A)
Number of subjects: 28
Study 9510365 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDA/MMC at a current of 15 mA for 20 minutes once a week for 8 weeks (group B)
Number of subjects: 28
Study 7844097 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical eye-blink conditioning in persons with autism
Number of subjects: 11
Study 7844097 — intervention group
Group type: COMPARATOR
Intervention: Classical eye-blink conditioning in matched controls
Number of subjects: 11
Study 29714697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive composite resin
Number of subjects: 60
Study 29714697 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal hybrid composite resin
Number of subjects: 60
Study 29714697 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer restorative
Number of subjects: 60
Study 26576838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-FPG group (FPG cut-off of 93 mg/dl for males and 92 mg/dl for females)
Number of subjects: 5039
Study 26576838 — intervention group
Group type: COMPARATOR
Intervention: Low-FPG group
Number of subjects: 5039
Study 24284908 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally facilitated/psychoeducational online support group
Number of subjects: 86
Study 24284908 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated/peer‐directed online support group
Number of subjects: 86
Study 24284908 — intervention group
Group type: COMPARATOR
Intervention: Nonactive participants
Number of subjects: 86
Study 22033466 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A2 promoter-driven conditionally replicative adenovirus (Ad/SA)
Number of subjects: 0
Study 22033466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with cetuximab or cisplatin plus Ad/SA
Number of subjects: 0
Study 22033466 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (EGFR-targeting anticancer drug)
Number of subjects: 0
Study 22033466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad/SA
Number of subjects: 0
Study 20436073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infliximab (IFX) 3 mg/kg at 0, 2, and 6 weeks
Number of subjects: 0
Study 20436073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19836989 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ catheter (ISC)
Number of subjects: 46
Study 19836989 — intervention group
Group type: COMPARATOR
Intervention: Axillary perineural catheter (APC)
Number of subjects: 46
Study 16953019 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and postpartum lactation support intervention
Number of subjects: 338
Study 16953019 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 338
Study 15247137 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1.2 mg) for 12 weeks
Number of subjects: 65
Study 15247137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 11401608 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievable benchmark feedback (experimental group; n = 35)
Number of subjects: 2978
Study 11401608 — intervention group
Group type: COMPARATOR
Intervention: Multimodal improvement intervention (comparison group; n = 35)
Number of subjects: 2978
Study 8989339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ICU PRISM score
Number of subjects: 780
Study 8989339 — intervention group
Group type: COMPARATOR
Intervention: Predicted mortality rates
Number of subjects: 780
Study 8424573 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg iv ketorolac twice, then 10 mg iv every 30 min as required, followed by 10 mg oral ketorolac every 4-6 h
Number of subjects: 221
Study 8424573 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral ketorolac
Number of subjects: 221
Study 8424573 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms iv fentanyl
Number of subjects: 221
Study 8424573 — intervention group
Group type: COMPARATOR
Intervention: 60 mg codeine plus 600 mg acetaminophen (C+A) orally every 4-6 h
Number of subjects: 221
Study 3673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 8
Study 3673660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29499122 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity for 10 days
Number of subjects: 2
Study 29499122 — intervention group
Group type: COMPARATOR
Intervention: Reduced daily movement for 10 days
Number of subjects: 2
Study 27576780 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation plus standardized stepped-care antihypertensive treatment
Number of subjects: 106
Study 27576780 — intervention group
Group type: COMPARATOR
Intervention: Standardized stepped-care antihypertensive treatment alone
Number of subjects: 106
Study 24742407 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic polypropylene mesh at the time of stoma formation
Number of subjects: 42
Study 24742407 — intervention group
Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 42
Study 23188096 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical team structure (Group H)
Number of subjects: 49
Study 23188096 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hierarchical team structure (Group NH)
Number of subjects: 49
Study 23188096 — intervention group
Group type: EXPERIMENTAL
Intervention: PGY2 to PGY5
Number of subjects: 49
Study 20019369 — intervention group
Group type: EXPERIMENTAL
Intervention: IVTA 4 mg
Number of subjects: 54
Study 20019369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18502105 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.9 Gy in 13 fractions
Number of subjects: 400
Study 18502105 — intervention group
Group type: COMPARATOR
Intervention: 39 Gy in 13 fractions
Number of subjects: 400
Study 15909489 — intervention group
Group type: EXPERIMENTAL
Intervention: Received contrast group
Number of subjects: 60
Study 15909489 — intervention group
Group type: COMPARATOR
Intervention: No contrast group
Number of subjects: 60
Study 12576945 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM only (n = 19)
Number of subjects: 47
Study 12576945 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM + PEEP (n = 20)
Number of subjects: 47
Study 12576945 — intervention group
Group type: COMPARATOR
Intervention: PEEP only (n = 8)
Number of subjects: 47
Study 12576945 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM (general)
Number of subjects: 47
Study 10568567 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 37
Study 10568567 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed pallidotomy after 6 months)
Number of subjects: 37
Study 8721124 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 17
Study 8721124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 17
Study 1791932 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.3 g/kg
Number of subjects: 0
Study 1791932 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.6 g/kg
Number of subjects: 0
Study 1791932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1791932 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (both doses)
Number of subjects: 0
Study 7100264 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 30
Study 7100264 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study 7100264 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone and Amitriptyline
Number of subjects: 30
Study 30234517 — intervention group
Group type: EXPERIMENTAL
Intervention: IPACK with ACB and modified PAI
Number of subjects: 86
Study 30234517 — intervention group
Group type: COMPARATOR
Intervention: PAI
Number of subjects: 86
Study 29216899 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic-reference comparisons
Number of subjects: 700
Study 29216899 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic-generic comparisons
Number of subjects: 700
Study 29216899 — intervention group
Group type: EXPERIMENTAL
Intervention: Average geometric mean ratio deviation
Number of subjects: 700
Study 29216899 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual ratios for AUCT
Number of subjects: 700
Study 29216899 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual ratios for Cmax
Number of subjects: 700
Study 25655515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycle exercise (40 min at 65% peak oxygen uptake)
Number of subjects: 14
Study 25655515 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy individuals, 14 subjects, 61 ± 5 years old, 12 men and 2 women)
Number of subjects: 14
Study 24343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P podcasts (7 podcasts over 2 weeks)
Number of subjects: 139
Study 24343191 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 139
Study 23008442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt coronary revascularization
Number of subjects: 381
Study 23008442 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy
Number of subjects: 381
Study 19068041 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian version of VEINES-QOL/Sym questionnaire
Number of subjects: 74
Study 17475963 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection plus radiotherapy (RT), n=31
Number of subjects: 52
Study 17475963 — intervention group
Group type: COMPARATOR
Intervention: Radical RT plus chemotherapy (RT), n=21
Number of subjects: 52
Study 17475963 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 52
Study 15612617 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg tablets (formulation 1)
Number of subjects: 0
Study 15612617 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg tablets (formulation 2)
Number of subjects: 0
Study 11732720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg single dose (Category I)
Number of subjects: 180
Study 11732720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 10 days (Category II)
Number of subjects: 180
Study 11732720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg single dose (Category III)
Number of subjects: 180
Study 11732720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg per week for 4 weeks (Category IV)
Number of subjects: 180
Study 9084916 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg once daily for 10 days
Number of subjects: 12
Study 9084916 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily for 10 days
Number of subjects: 12
Study 7525123 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 18
Study 3296263 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-free diet
Number of subjects: 56
Study 3296263 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-free diet (placebo)
Number of subjects: 56
Study 3296263 — intervention group
Group type: COMPARATOR
Intervention: No dietary restrictions (control)
Number of subjects: 56
Study 31346923 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention protocol addressing psychosocial risk factors for delayed return to work.
Number of subjects: 0
Study 31346923 — intervention group
Group type: COMPARATOR
Intervention: Usual (stepped) care arrangements.
Number of subjects: 0